# Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

> **NCT00333411** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 360 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BIRT 2584 XX
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00333411
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2014-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333411, "Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00333411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*